Literature DB >> 33218135

Chronic Pain Treatment Strategies in Parkinson's Disease.

Amber Edinoff1, Niro Sathivadivel1, Timothy McBride2, Allyson Parker2, Chikezie Okeagu3, Alan D Kaye3,4, Adam M Kaye5, Jessica S Kaye5, Rachel J Kaye6, Meeta M Sheth4, Omar Viswanath4,6,7,8,9, Ivan Urits4,10.   

Abstract

Neurological disorders, including Parkinson's disease (PD), have increased in prevalence and are expected to further increase in the coming decades. In this regard, PD affects around 3% of the population by age 65 and up to 5% of people over the age of 85. PD is a widely described, physically and mentally disabling neurodegenerative disorder. One symptom often poorly recognized and under-treated by health care providers despite being reported as the most common non-motor symptom is the finding of chronic pain. Compared to the general population of similar age, PD patients suffer from a significantly higher level and prevalence of pain. The most common form of pain reported by Parkinson's patients is of musculoskeletal origin. One of the most used combination drugs for PD is Levodopa-Carbidopa, a dopamine precursor that is converted to dopamine by the action of a naturally occurring enzyme called DOPA decarboxylase. Pramipexole, a D2 dopamine agonist, and apomorphine, a dopamine agonist, and Rotigotine, a dopamine receptor agonist, have showed efficacy on PD-associated pain. Other treatments that have shown efficacy in treating pain of diverse etiologies are acetaminophen, Nonsteroidal anti-inflammatory drugs (NSAIDs), and cyclooxygenase-2 (COX-2) inhibitors. Opioids and opioid-like medications such as oxycodone, morphine, tramadol, and codeine are also commonly employed in treatment of chronic pain in PD. Other opioid related medications such as Tapentadol, a central-acting oral analgesic with combined opioid and noradrenergic properties, and Targinact, a combination of the opioid agonist oxycodone and the opioid antagonist naloxone have shown improvement in pain. Anticonvulsants such as gabapentin, pregabalin, lamotrigine, carbamazepine and tricyclic antidepressants (TCAs) can be trialed when attempting to manage chronic pain in PD. The selective serotonin and noradrenaline reuptake inhibitors (SNRIs) also possess pain relieving and antidepressant properties, but carry less of the risk of anticholinergic side effects seen in TCAs. Deep brain stimulation (DBS) of the subthalamic nucleus (STN) has been shown in multiple studies to be effective against various types of PD associated pain symptoms. Massage therapy (MT) is one of the most common forms of complementary and alternative medicine. Studies have shown that pressure applied during MT may stimulate vagal activity, promoting reduced anxiety and pain, as well as increasing levels of serotonin. In a survey study of PD patients, rehabilitative therapy and physical therapy were rated as the most effective for pain reduction, though with only temporary relief but these studies were uncontrolled. Yoga has been studied for patients with a wide array of neurological disorders. In summary, PD pathology is thought to have a modulating effect on pain sensation, which could amplify pain. This could help explain a portion of the higher incidence of chronic pain felt by PD patients. A treatment plan can be devised that may include dopaminergic agents, acetaminophen, NSAIDs, opioids, antidepressants, physical therapies, DBS and other options discussed in this review. A thorough assessment of patient history and physical examination should be made in patients with PD so chronic pain may be managed effectively.

Entities:  

Keywords:  Parkinson’s disease; chronic pain; neuropathic pain; treatment strategies

Year:  2020        PMID: 33218135      PMCID: PMC7768530          DOI: 10.3390/neurolint12030014

Source DB:  PubMed          Journal:  Neurol Int        ISSN: 2035-8385


  122 in total

1.  Treatment for Helicobacter pylori infection and risk of Parkinson's disease in Denmark.

Authors:  H H Nielsen; J Qiu; S Friis; L Wermuth; B Ritz
Journal:  Eur J Neurol       Date:  2012-01-17       Impact factor: 6.089

Review 2.  Emerging analgesic drugs for Parkinson's disease.

Authors:  Santiago Perez-Lloret; María Verónica Rey; Estelle Dellapina; Jean Pellaprat; Christine Brefel-Courbon; Olivier Rascol
Journal:  Expert Opin Emerg Drugs       Date:  2012-04-25       Impact factor: 4.191

3.  Consumption of dairy products and risk of Parkinson's disease.

Authors:  Honglei Chen; Eilis O'Reilly; Marjorie L McCullough; Carmen Rodriguez; Michael A Schwarzschild; Eugenia E Calle; Michael J Thun; Alberto Ascherio
Journal:  Am J Epidemiol       Date:  2007-01-31       Impact factor: 4.897

Review 4.  Parkinson's Disease and Parkinsonism.

Authors:  Michael T Hayes
Journal:  Am J Med       Date:  2019-03-16       Impact factor: 4.965

5.  Impact of pain and pain subtypes on the quality of life of patients with Parkinson's disease.

Authors:  Seong-Min Choi; Byeong C Kim; Hyun-Jung Jung; Geum-Jin Yoon; Kyung Wook Kang; Kang-Ho Choi; Joon-Tae Kim; Seung-Han Lee; Man-Seok Park; Myeong-Kyu Kim; Ki-Hyun Cho
Journal:  J Clin Neurosci       Date:  2017-08-24       Impact factor: 1.961

6.  Exploring the relationship between Parkinson disease and restless legs syndrome.

Authors:  William G Ondo; Kevin Dat Vuong; Joseph Jankovic
Journal:  Arch Neurol       Date:  2002-03

Review 7.  Pain in Parkinson's disease: new concepts in pathogenesis and treatment.

Authors:  Katarina Rukavina; Valentina Leta; Carolina Sportelli; Yazead Buhidma; Susan Duty; Marzia Malcangio; Kallol Ray Chaudhuri
Journal:  Curr Opin Neurol       Date:  2019-08       Impact factor: 5.710

8.  Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial.

Authors:  Claudia Trenkwalder; K Ray Chaudhuri; Pablo Martinez-Martin; Olivier Rascol; Reinhard Ehret; Martin Vališ; Maria Sátori; Anna Krygowska-Wajs; Maria J Marti; Karen Reimer; Alexander Oksche; Mark Lomax; Julia DeCesare; Michael Hopp
Journal:  Lancet Neurol       Date:  2015-10-19       Impact factor: 44.182

9.  Striatal histone modifications in models of levodopa-induced dyskinesia.

Authors:  Anthony P Nicholas; Farah D Lubin; Penelope J Hallett; Padmapriya Vattem; Paula Ravenscroft; Erwan Bezard; Shaobo Zhou; Susan H Fox; Jonathan M Brotchie; J David Sweatt; David G Standaert
Journal:  J Neurochem       Date:  2008-07-01       Impact factor: 5.372

Review 10.  Diagnostic Criteria for Parkinson's Disease: From James Parkinson to the Concept of Prodromal Disease.

Authors:  Luca Marsili; Giovanni Rizzo; Carlo Colosimo
Journal:  Front Neurol       Date:  2018-03-23       Impact factor: 4.003

View more
  6 in total

Review 1.  Role of Environmental Toxicants on Neurodegenerative Disorders.

Authors:  Masarat Nabi; Nahida Tabassum
Journal:  Front Toxicol       Date:  2022-05-11

2.  NLX-112, a highly selective 5-HT1A receptor biased agonist, does not exhibit misuse potential in male rats or macaques.

Authors:  R Depoortère; J Bergman; P M Beardsley; R I Desai; C A Paronis; D M Walentiny; M A Varney; A Newman-Tancredi
Journal:  Neuropharmacology       Date:  2022-03-09       Impact factor: 5.250

3.  Personalized Biometrics of Physical Pain Agree with Psychophysics by Participants with Sensory over Responsivity.

Authors:  Jihye Ryu; Tami Bar-Shalita; Yelena Granovsky; Irit Weissman-Fogel; Elizabeth B Torres
Journal:  J Pers Med       Date:  2021-02-02

4.  Chiropractic care of Parkinson's disease and deformity.

Authors:  Eric Chun-Pu Chu; Alan Te-Chang Chen; Ricky Chiang
Journal:  J Med Life       Date:  2022-05

5.  The Impact of Depression Symptoms in Patients with Parkinson's Disease: A Novel Case-Control Investigation.

Authors:  Ana María Jiménez-Cebrián; Ricardo Becerro-de-Bengoa-Vallejo; Marta Elena Losa-Iglesias; Daniel López-López; César Calvo-Lobo; Patricia Palomo-López; Carlos Romero-Morales; Emmanuel Navarro-Flores
Journal:  Int J Environ Res Public Health       Date:  2021-03-01       Impact factor: 3.390

6.  Opicapone versus placebo in the treatment of Parkinson's disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial.

Authors:  K Ray Chaudhuri; Per Odin; Joaquim J Ferreira; Angelo Antonini; Olivier Rascol; Mónica M Kurtis; Alexander Storch; Kirsty Bannister; Patrício Soares-da-Silva; Raquel Costa; Diogo Magalhães; José Francisco Rocha
Journal:  BMC Neurol       Date:  2022-03-12       Impact factor: 2.474

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.